300
Participants
Start Date
September 30, 2025
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2030
CGM device - Metformin group
Individuals randomized to metformin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
CGM device - Insulin group
Individuals randomized to insulin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
University of Alabama, Tuscaloosa
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus
Premier Health - Miami Valley Hospital, Dayton
Massachusetts General Hospital, Boston
The George Washington University Biostatistics Center
OTHER
DexCom, Inc.
INDUSTRY
Ohio State University
OTHER